Less than 6 months after announcing the opening of its next investment fund, Cottonwood Technology Fund III has revealed its fourth impact investment. This time the infusion of cash is going to Enschede’s medical chip expert Sencure and will be used, along with an additional 500k from co-investor Lumana Invest, to file patent applications to protect the company’s unique IP, as well as to accelerate the global rollout of its products, including its biometric sensing chip.
Sencure’s biometric sensing chip is the result of five years’ effort in designing electronic systems and signal processing algorithms for electrophysiological diagnostic and monitoring systems to deliver medical-grade accuracy. It’s set to significantly outperform medical chips from current manufacturers in terms of both price and quality. Competitive advantages include ultra-low power consumption and smaller size, aimed at wide-scale market adoption. With the biometric sensing chip, the company is looking to reach wearable solutions that fit a wide range of applications for medtech companies, including remote patient monitoring and diagnostics for cardiac cases, COPD, children’s asthma, neurological cases and EEG, as well as ICU-grade ventilation and monitoring of vital signs.
“Cottonwood has known and worked with Sencure’s team members for several years now, and strongly believes in their ability to further develop the company,” says Alain le Loux, General Partner of Cottonwood Technology Fund. “We contacted all potential customers for Sencure and were surprised to learn Sencure’s biometric sensing chip is the first in the market to be recognized by customers as ‘best-in-class technology.’”